Maduck Sean sold $2.2M of CORT

Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $88.35 ($87.33–$89.31, $2.21M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Jul 6, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

A $2.21M open-market sale by an officer can create minor sentiment noise, but the presence of a pre-arranged 10b5-1 plan reduces interpretive weight.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

The article lacks context on total insider holdings history, other concurrent insider trades, and whether the sale was part of a broader scheduled program.

Relevance 5/10Novelty 3/10Timing: Filed after-hours (2026-07-06 16:44 ET) for a 2026-07-01 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported by officer Maduck Sean.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics Form 4 shows officer Maduck Sean sold 25,000 shares in open-market trades for about $2.21M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction is typically small and short-lived unless accompanied by other new company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan; the article provides no new operational, financial, or regulatory developments.

Market effects

No direct sector read-through; this is company-specific insider liquidity activity.

None indicated.

None indicated.

Counterpoint

Insider sales under a 10b5-1 plan can be purely mechanical (tax/liquidity) and may not signal reduced confidence.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction; officer Maduck Sean sold shares under a 10b5-1 plan.

  • Maduck Sean

    Officer who executed the open-market sale of 25,000 shares on 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.